Table 1.
Patient Characteristics and Apixaban Dosing
| Dosing Regimen |
5 mg Twice Daily |
2.5 mg Twice Daily |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total | 5 mg Twice Daily | 2.5 mg Twice Daily | P Value | Women | Men | P Value | Women | Men | P Value | |
| Total | 115 | 91 (79) | 24 (21) | 31 (34) | 60 (66) | 15 (63) | 9 (38) | |||
| Age (y) | 80 (77-84) | 79 (76-82) | 86 (82-87) | <0.001a | 78 (76-80) | 80 (76-82) | 0.590a | 84 (80-88) | 87 (84-87) | 0.352a |
| Weight (kg) | 77 (67-86) | 80 (72-91) | 58 (54-74) | <0.001a | 70 (62-80) | 81 (77-93) | <0.001a | 56 (51-58) | 76 (73-83) | 0.002a |
| BMI (kg/m2) | 25 (23-28) | 26 (23-29) | 23 (20-25) | 0.002a | 24 (22-28) | 26 (24-29) | 0.233a | 22 (19-24) | 25 (24-28) | 0.008a |
| Male | 69 (60) | 60 (66) | 9 (38) | 0.011b | ||||||
| Race | 0.134b | 0.118b | 0.525b | |||||||
| Asian | 6 (5) | 3 (3) | 3 (13) | 0 (0) | 3 (5) | 3 (20) | 0 (0) | |||
| Black or African American | 11 (10) | 8 (9) | 3 (13) | 5 (16) | 3 (5) | 2 (13) | 1 (11) | |||
| White | 98 (85) | 80 (88) | 18 (75) | 26 (84) | 54 (90) | 10 (67) | 8 (89) | |||
| Ethnicity | 0.696b | 0.116b | 0.533b | |||||||
| Hispanic or Latino | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |||
| Not Hispanic or Latino | 104 (90) | 83 (91) | 21 (88) | 26 (84) | 57 (95) | 14 (93) | 7 (78) | |||
| Not reported | 11 (10) | 8 (9) | 3 (13) | 5 (16) | 3 (5) | 1 (7) | 2 (22) | |||
| Self-reported health | 105d | 83 | 22 | 0.042b | 26 | 57 | 0.238b | 14 | 8 | 0.046b |
| Excellent | 8 (8) | 8 (10) | 0 (0) | 3 (12) | 5 (9) | 0 (0) | 0 (0) | |||
| Very good | 45 (43) | 39 (47) | 6 (27) | 8 (31) | 31 (54) | 3 (21) | 3 (38) | |||
| Good | 38 (36) | 28 (34) | 10 (45) | 12 (46) | 16 (28) | 9 (64) | 1 (13) | |||
| Fair | 14 (13) | 8 (10) | 6 (27) | 3 (12) | 5 (9) | 2 (14) | 4 (50) | |||
| ADL | 6 (6-6)d | 6 (6-6) | 6 (6-6) | 0.623a | 6 (6-6) | 6 (6-6) | 0.516a | 6 (6-6) | 6 (6-6) | >0.999a |
| IADL | 8 (8-8)d | 8 (8-8) | 8 (8-8) | 0.727a | 8 (8-8) | 8 (8-8) | 0.387a | 8 (8-8) | 8 (8-8) | 0.188a |
| Creatinine (mg/dL) | 1.00 ± 0.30, 1.00 | 1.00 ± 0.30, 1.00 | 1.00 ± 0.30, 1.00 | 0.835c | 0.90 ± 0.30, 1.00 | 1.10 ± 0.30, 1.00 | 0.005c | 0.90 ± 0.30, 1.00 | 1.20 ± 0.20, 1.00 | 0.010c |
| Range | 0.50-2.10 | 0.50-2.10 | 0.50-1.50 | 0.50-2.10 | 0.70-2.00 | 0.50-1.40 | 0.80-1.50 | |||
| Creatinine clearance (mL/min) | 63 ± 20, 61 | 68 ± 19, 67 | 47 ± 12, 46 | <0.001c | 63 ± 20, 57 | 70 ± 18, 68 | 0.095c | 44 ± 13, 43 | 51 ± 11, 49 | 0.207c |
| Range | 25-122 | 28-122 | 25-75 | 28-106 | 30-122 | 25-75 | 38-69 | |||
| eGFR CKD-EPI (mL/min/1.73 m2) | 69 (55-80) | 70 (58-81) | 60 (50-77) | 0.105a | 70 (52-82) | 70 (58-80) | 0.741a | 66 (52-78) | 57 (46-59) | 0.387a |
| CHA2DS2-VASc score | 4 (3-5) | 4 (3-5) | 5 (3-6) | 0.041a | 4 (4-5) | 4 (3-5) | 0.055a | 5 (4-6) | 4 (3-5) | 0.143a |
| HAS-BLED score | 2 (1-2) | 2 (1-2) | 2 (1-2) | 0.607a | 2 (1-2) | 2 (1-2) | 0.732a | 2 (1-2) | 2 (1-2) | 0.793a |
| Clinical Frailty Scored | 3 (2-3) | 2 (2-3) | 3 (2-3) | 0.400a | 3 (2-4) | 2 (1-3) | 0.106a | 3 (2-3) | 3 (1-4) | 0.619a |
| Charlson Comorbidity Score | 5 (4-6) | 4 (4-6) | 6 (5-7) | 0.012a | 4 (3-6) | 5 (4-6) | 0.100a | 6 (4-6) | 6 (5-7) | 0.624a |
| Coadministration moderate CYP3A4/5-P-gp inhibitors (no inhibitors) | 95 (83) | 76 (84) | 19 (79) | 0.762b | 26 (84) | 50 (83) | 1.00b | 12 (80) | 7 (78) | 1.00b |
| Number of daily medications | 5 (4-7) | 5 (4-7) | 5 (4-7) | 0.953a | 5 (4-8) | 6 (4-7) | 0.889a | 5 (4-6) | 5 (4-8) | 0.832a |
Values are n (%), median (IQR), or mean ± SD, median; percentages may not add to 100 due to rounding.
ADL = activities of daily living; BMI = body mass index; CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration; eGFR = estimated glomerular filtration rate; IADL = independent activities of daily living.
a
Wilcoxon rank-sum tests.
b
Chi-square tests.
c
Unpaired 2-sided t-tests.
d
Not assessed in 10 subjects included from ACCOuNT Consortium: total (N = 105), 5 mg twice daily (N = 83, women N = 26, men N = 57), 2.5 mg twice daily (N = 22, women N = 14, men N = 8).